Clinical Trials

MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing (MORE-CRT MPP) Identifier: NCT02006069

The purpose of this Clinical investigation is to assess the impact of the Multi Point Pacing (MPP) feature at 12 months in the treatment of patients not responding to standard Cardiac Resynchronization Therapy (CRT) after 6 months.

Please contact Jonathon Foote for more information. Identifier: NCT01972295

This is an observational, prospective, non-randomized, multicenter study with the following objectives: (1) to compile real-world clinical outcomes data for WATCHMAN Left Atrial Appendage Closure Technology in patients who are implanted with the WATCHMAN device in a commercial clinical setting and (2) to collect health care usage data that may be needed for reimbursement of WATCHMAN technology in certain countries.

Please contact Jonathon Foote for more information. Id: NCT02030418

LEADLESS is the world's smallest pacemaker. The LEADLESS trial is a prospective, non-randomized, single-arm, international multicenter, clinical safety and effectiveness investigation.

Please contact Johnathon Foote for more information.

Page 3 of 3
  • Professor Sanders says...

    Atrial fibrillation is a consequence of several reversible risk factors - high blood pressure, diabetes, obesity, sleep apnoea, and excessive alcohol. Your management of atrial fibrillation must include strict control of these risk factors.